Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00252759 |
The purposes of this study are:
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | A Nested Case-Control Study to Determine the Relative Risk of and Risk Factors for Interstitial Lung Disease in a Cohort of NSCLC Patients Treated With and Without Gefitinib |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | AstraZeneca Japan Medical Director, MD | AstraZeneca |
Study ID Numbers: | D791AL00002, V-15-33, OZV1533 |
Study First Received: | November 14, 2005 |
Last Updated: | December 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00252759 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Thoracic Neoplasms Non-small cell lung cancer Lung Diseases, Interstitial Respiratory Tract Diseases Lung Neoplasms |
Lung Diseases Gefitinib Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type |